Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.

ABSTRACT:

Background

Bedaquiline and delamanid are newly available drugs for treating multidrug-resistant tuberculosis (MDR-TB); however, there are limited data guiding their use and no comparison studies.

Methods

We conducted a prospective, observational study among patients with MDR-TB in Georgia who were receiving a bedaquiline- or delamanid-based treatment regimen. Monthly sputum cultures, minimal inhibitory concentration testing, and adverse event monitoring were performed. Primary outcomes were culture conversion rates and clinical outcomes. Targeted maximum likelihood estimation and super learning were utilized to produce a covariate-adjusted proportion of outcomes for each regimen.

Results

Among 156 patients with MDR-TB, 100 were enrolled and 95 were receiving a bedaqui

SUBMITTER: Kempker RR 

PROVIDER: S-EPMC7713674 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature